Table 2.
Summary of Baseline Demographics and Clinical Characteristics
| Patient Profile | Mean | SD | Range | n/N (%) |
|---|---|---|---|---|
| Sex | ||||
| Male | — | — | — | 16/25 (64.0) |
| Female | — | — | — | 9/25 (36.0) |
| Intubated | — | — | — | 25/25 (100) |
| Age, y | 47.6 | 19.52 | 10, 76 | 25/25 (100) |
| Overall duration, days | 9.2 | 5.70 | 3, 20 | 25/25 (100) |
| SE | 2.2 | 2.30 | 1, 12 | 25/25 (100) |
| RSE | 3.0 | 2.63 | 1, 13 | 25/25 (100) |
| SRSE | 6.1 | 5.16 | 1, 19 | 25/25 (100) |
| NIHSS total score | 33.4 | 4.87 | 20, 38 | 25/25 (100) |
| STESS total score | 3.4 | 1.00 | 1, 5 | 25/25 (100) |
| GCS total score | 3.8 | 1.65 | 3, 10 | 24/25 (96) |
| RASS score | –4.8 | 0.49 | –5, –3 | 23/25 (92) |
| mRS‐9Q score | 5.0 | 0.00 | 5, 5 | 24/25 (96) |
| CGI‐S score | 6.9 | 0.28 | 6, 7 | 25/25 (100) |
| Past wean attempts | 2.0 | 1.97 | 0, 8 | 25/25 (100) |
| TLA History a (Safety Population; N = 25) | Standard Dose | High Dose | Total | Total % |
| Ketamine | 4 | 0 | 4 | 16 |
| Midazolam | 13 | 4 | 17 | 68 |
| Pentobarbital | 6 | 3 | 9 | 36 |
| Propofol | 16 | 4 | 20 | 80 |
SD = standard deviation; CI = confidence interval; SE = status epilepticus; RSE = refractory status epilepticus; SRSE = super‐refractory status epilepticus; NIHSS = National Institutes of Health Stroke Scale; STESS = Status Epilepticus Severity Score; GCS = Glasgow Coma Scale; RASS = Richmond Agitation‐Sedation Scale; mRS‐9Q = Modified Rankin Scale‐9Q; CGI‐S = Clinical Global Impression‐Severity.
a
Current episode of SE.